



alirocumab 75mg / 150mg solution for injection in pre-filled pen (Praluent®)

Sanofi-Aventis Ltd

10 May 2019

ADVICE: in the absence of a submission from the holder of the marketing authorisation **alirocumab (Praluent®)** is not recommended for use within NHSScotland.

Indication under review: In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:

- in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland in adults with established atherosclerotic cardiovascular disease outwith the restriction specified in SMC advice (1147/16). Note that SMC advice (1147/16) remains valid.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman
Scottish Medicines Consortium**